Загрузка...
Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
INTRODUCTION: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC, henc...
Сохранить в:
| Опубликовано в: : | Expert Opin Investig Drugs |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681663/ https://ncbi.nlm.nih.gov/pubmed/31215251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2019.1632289 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|